A role for peripheral somatostatin receptors in counter-irritation-induced analgesia

S. M. Carlton, S. Zhou, B. Kraemer, R. E. Coggeshall

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Our hypothesis is that peripheral somatostatin (SRIF) has a role in counter-irritation-induced analgesia. Our paradigm involves the reduction of nociceptive behaviors produced by primary noxious stimuli (formalin or complete Freund's adjuvant [CFA] in the rat hind paw) by a counter-irritating stimulus (capsaicin [CAP] in the tail or muzzle). Activation of peripheral SRIF receptors is key since an SRIF receptor antagonist cyclo-somatostatin (c-SOM) and SRIF antibodies in the hind paw attenuate the counter-irritation-induced analgesia of both formalin and more persistent CFA nociception. Specificity of c-SOM is shown by reversal of its effects with octreotide, a SRIF analog. Injection of formalin in one hind paw and c-SOM in the other does not reduce the counter-irritation analgesia demonstrating local action of the c-SOM. Approximately 33% of peripheral sensory axons contain SRIF, which could release the peptide to activate SRIF receptors on cutaneous axons. Intraplantar naloxone has no effect on the counter-irritation analgesia indicating that SRIF is not activating opioid receptors. These results indicate that in addition to the classic central descending noxious inhibitory control systems that underlie counter-irritation-induced analgesia, there is a peripheral contribution arising from activation of SRIF receptors. Identifying a peripheral contribution of SRIF to mechanisms of counter-irritation analgesia offers opportunities for peripheral therapy.

Original languageEnglish (US)
Pages (from-to)499-508
Number of pages10
JournalNeuroscience
Volume120
Issue number2
DOIs
StatePublished - Aug 22 2003

Fingerprint

Somatostatin Receptors
Analgesia
Somatostatin
Formaldehyde
Freund's Adjuvant
Axons
Nociception
Octreotide
Capsaicin
Opioid Receptors
Naloxone
Tail
Skin
Peptides
Injections
Antibodies

Keywords

  • Complete Freund's adjuvant
  • Cyclo-somatostatin
  • Diffuse noxious inhibitory controls
  • DNIC
  • Endogenous analgesia
  • Non-opioid

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

A role for peripheral somatostatin receptors in counter-irritation-induced analgesia. / Carlton, S. M.; Zhou, S.; Kraemer, B.; Coggeshall, R. E.

In: Neuroscience, Vol. 120, No. 2, 22.08.2003, p. 499-508.

Research output: Contribution to journalArticle

Carlton, S. M. ; Zhou, S. ; Kraemer, B. ; Coggeshall, R. E. / A role for peripheral somatostatin receptors in counter-irritation-induced analgesia. In: Neuroscience. 2003 ; Vol. 120, No. 2. pp. 499-508.
@article{ae7b3d23d1044c93b2fb2f53e8efe53d,
title = "A role for peripheral somatostatin receptors in counter-irritation-induced analgesia",
abstract = "Our hypothesis is that peripheral somatostatin (SRIF) has a role in counter-irritation-induced analgesia. Our paradigm involves the reduction of nociceptive behaviors produced by primary noxious stimuli (formalin or complete Freund's adjuvant [CFA] in the rat hind paw) by a counter-irritating stimulus (capsaicin [CAP] in the tail or muzzle). Activation of peripheral SRIF receptors is key since an SRIF receptor antagonist cyclo-somatostatin (c-SOM) and SRIF antibodies in the hind paw attenuate the counter-irritation-induced analgesia of both formalin and more persistent CFA nociception. Specificity of c-SOM is shown by reversal of its effects with octreotide, a SRIF analog. Injection of formalin in one hind paw and c-SOM in the other does not reduce the counter-irritation analgesia demonstrating local action of the c-SOM. Approximately 33{\%} of peripheral sensory axons contain SRIF, which could release the peptide to activate SRIF receptors on cutaneous axons. Intraplantar naloxone has no effect on the counter-irritation analgesia indicating that SRIF is not activating opioid receptors. These results indicate that in addition to the classic central descending noxious inhibitory control systems that underlie counter-irritation-induced analgesia, there is a peripheral contribution arising from activation of SRIF receptors. Identifying a peripheral contribution of SRIF to mechanisms of counter-irritation analgesia offers opportunities for peripheral therapy.",
keywords = "Complete Freund's adjuvant, Cyclo-somatostatin, Diffuse noxious inhibitory controls, DNIC, Endogenous analgesia, Non-opioid",
author = "Carlton, {S. M.} and S. Zhou and B. Kraemer and Coggeshall, {R. E.}",
year = "2003",
month = "8",
day = "22",
doi = "10.1016/S0306-4522(03)00337-3",
language = "English (US)",
volume = "120",
pages = "499--508",
journal = "Neuroscience",
issn = "0306-4522",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - A role for peripheral somatostatin receptors in counter-irritation-induced analgesia

AU - Carlton, S. M.

AU - Zhou, S.

AU - Kraemer, B.

AU - Coggeshall, R. E.

PY - 2003/8/22

Y1 - 2003/8/22

N2 - Our hypothesis is that peripheral somatostatin (SRIF) has a role in counter-irritation-induced analgesia. Our paradigm involves the reduction of nociceptive behaviors produced by primary noxious stimuli (formalin or complete Freund's adjuvant [CFA] in the rat hind paw) by a counter-irritating stimulus (capsaicin [CAP] in the tail or muzzle). Activation of peripheral SRIF receptors is key since an SRIF receptor antagonist cyclo-somatostatin (c-SOM) and SRIF antibodies in the hind paw attenuate the counter-irritation-induced analgesia of both formalin and more persistent CFA nociception. Specificity of c-SOM is shown by reversal of its effects with octreotide, a SRIF analog. Injection of formalin in one hind paw and c-SOM in the other does not reduce the counter-irritation analgesia demonstrating local action of the c-SOM. Approximately 33% of peripheral sensory axons contain SRIF, which could release the peptide to activate SRIF receptors on cutaneous axons. Intraplantar naloxone has no effect on the counter-irritation analgesia indicating that SRIF is not activating opioid receptors. These results indicate that in addition to the classic central descending noxious inhibitory control systems that underlie counter-irritation-induced analgesia, there is a peripheral contribution arising from activation of SRIF receptors. Identifying a peripheral contribution of SRIF to mechanisms of counter-irritation analgesia offers opportunities for peripheral therapy.

AB - Our hypothesis is that peripheral somatostatin (SRIF) has a role in counter-irritation-induced analgesia. Our paradigm involves the reduction of nociceptive behaviors produced by primary noxious stimuli (formalin or complete Freund's adjuvant [CFA] in the rat hind paw) by a counter-irritating stimulus (capsaicin [CAP] in the tail or muzzle). Activation of peripheral SRIF receptors is key since an SRIF receptor antagonist cyclo-somatostatin (c-SOM) and SRIF antibodies in the hind paw attenuate the counter-irritation-induced analgesia of both formalin and more persistent CFA nociception. Specificity of c-SOM is shown by reversal of its effects with octreotide, a SRIF analog. Injection of formalin in one hind paw and c-SOM in the other does not reduce the counter-irritation analgesia demonstrating local action of the c-SOM. Approximately 33% of peripheral sensory axons contain SRIF, which could release the peptide to activate SRIF receptors on cutaneous axons. Intraplantar naloxone has no effect on the counter-irritation analgesia indicating that SRIF is not activating opioid receptors. These results indicate that in addition to the classic central descending noxious inhibitory control systems that underlie counter-irritation-induced analgesia, there is a peripheral contribution arising from activation of SRIF receptors. Identifying a peripheral contribution of SRIF to mechanisms of counter-irritation analgesia offers opportunities for peripheral therapy.

KW - Complete Freund's adjuvant

KW - Cyclo-somatostatin

KW - Diffuse noxious inhibitory controls

KW - DNIC

KW - Endogenous analgesia

KW - Non-opioid

UR - http://www.scopus.com/inward/record.url?scp=0141957908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141957908&partnerID=8YFLogxK

U2 - 10.1016/S0306-4522(03)00337-3

DO - 10.1016/S0306-4522(03)00337-3

M3 - Article

VL - 120

SP - 499

EP - 508

JO - Neuroscience

JF - Neuroscience

SN - 0306-4522

IS - 2

ER -